Just a reminder about DM/SCRN relationship Pursuant to the Definitive Agreement, the Company was issued 36,000,000 common shares in the capital (the "Common Shares") of ScreenPro at a deemed price of $0.05 per Common Share for an aggregate purchase price of $1,800,000.
No finder's fee was payable in connection with the Definitive Agreement, and ScreenPro does not assume any debt. The sale does not constitute a fundamental change or result in a change of business, nor is it expected to result in a change of control within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange (the "CSE") and or the Toronto Venture Exchange (the "TSX.V").
Marshall Gunter, CEO of the Company commented, "We expect the sale of Concierge to benefit both Datametrex and ScreenPro in a number of ways. The stock issued to the company from this divestiture brings Datametrex a very good long-term investment in a great company. ScreenPro grows its core medical business, and this allows Datametrex management team to spend more time on our core artificial intelligence business. We will use this positive push to continue to look for tech opportunities to accelerate further our AI business portfolio."